News
Europital forecast 30% CAGR from UK biotech for three years
Europital – the global provider of medical management services for clinical research and drug development – announces it is opening a UK site to further expand its services to the UK biotech industry. The company is already working with...
News
Informa Markets in India all set to host the 9th edition of InnoPack Pharma Confex, virtually this year
CPhI Conferences India, a division of Informa Markets in India, which hosts a number of successful pharmaceutical conferences, has announced the 9th Annual InnoPack Pharma Confex slated for 3rd and 4th September 2020, this year in a virtual format....
News
Perigord becomes the most certified supplier of artwork solutions to the Life Science industry
Perigord confirms, that in achieving its latest certification ISO 27001, that they are the only Global provider of Artwork Management Systems (AMS) to the Life Science industry to be certified by BSI to ISO 27001, ISO 9001 and PS...
News
Clinerion protects security of Patient Network Explorer user accounts with 2-step authentication
The “Clinerion PNEx Authenticator” app gives users of Clinerion’s Patient Network Explorer additional data security with 2-step authentication.
To protect Patient Network Explorer user accounts from breach, Clinerion is activating a second verification step during the sign-in process. In addition...
Drug Research
Evotec and Novo Nordisk form strategic alliance to develop novel therapies for kidney diseases
Evotec SE and Novo Nordisk announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease.
Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular...
News
BMS and Dragonfly Therapeutics Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program
Bristol Myers Squibb and Dragonfly Therapeutics, Inc. announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life...
Clinical Trials
Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer
Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce approval from the Israeli Ministry of Health to proceed with their clinical trial...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.